(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of 0.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Arcus Biosciences's revenue in 2025 is $258,000,000.On average, 5 Wall Street analysts forecast RCUS's revenue for 2025 to be $13,106,343,286, with the lowest RCUS revenue forecast at $8,467,313,760, and the highest RCUS revenue forecast at $17,516,755,341. On average, 5 Wall Street analysts forecast RCUS's revenue for 2026 to be $17,359,263,305, with the lowest RCUS revenue forecast at $4,233,656,880, and the highest RCUS revenue forecast at $28,524,263,229.
In 2027, RCUS is forecast to generate $29,193,286,857 in revenue, with the lowest revenue forecast at $18,985,834,278 and the highest revenue forecast at $39,339,774,777.